Show simple item record

AuthorZidan, Amani
AuthorAwaisu, Ahmed
AuthorKheir, Nadir
AuthorMahfoud, Ziyad
AuthorKaddoura, Rasha
AuthorAlYafei, Sumaya
Available date2021-04-22T13:00:30Z
Publication Date2016
Publication NameBMJ Open
ResourceScopus
URIhttp://dx.doi.org/10.1136/bmjopen-2016-012141
URIhttp://hdl.handle.net/10576/18326
AbstractIntroduction: Acute coronary syndrome (ACS) is one of the leading causes of morbidity and mortality worldwide. Secondary cardiovascular risk reduction therapy (consisting of an aspirin, a ?-blocker, an ACE inhibitor or an angiotensin II receptor blocker and a statin) is needed for all patients with ACS. Less than 80% of patients with ACS in Qatar use this combination after discharge. This study is aimed to evaluate the effectiveness of clinical pharmacist-delivered intervention at discharge and tailored follow-up postdischarge on decreasing hospital readmissions, emergency department (ED) visits and mortality among patients with ACS. Methods and analysis: A prospective, randomised controlled trial will be conducted at the Heart Hospital in Qatar. Patients are eligible for enrolment if they are at least 18 years of age and are discharged from any non-surgical cardiology service with ACS. Participants will be randomised into 1 of 3 arms: (1) 'control' arm which includes patients discharged during weekends or after hours; (2) 'clinical pharmacist delivered usual care at discharge' arm which includes patients receiving the usual care at discharge by clinical pharmacists; and (3) 'clinical pharmacist-delivered structured intervention at discharge and tailored follow-up postdischarge' arm which includes patients receiving intensive structured discharge interventions in addition to 2 follow-up sessions by intervention clinical pharmacists. Outcomes will be measured by blinded research assistants at 3, 6 and 12 months after discharge and will include: all-cause hospitalisations and cardiac-related hospital readmissions (primary outcome), all-cause mortality including cardiac-related mortality, ED visits including cardiac-related ED visits, adherence to medications and treatment burden. Percentage of readmissions between the 3 arms will be compared on intent-to-treat basis using ?2 test with Bonferroni's adjusted pairwise comparisons if needed. Ethics and dissemination: The study was ethically approved by the Qatar University and the Hamad Medical Corporation Institutional Review Boards. The results shall be disseminated in international conferences and peer-reviewed publications.
Languageen
PublisherBMJ Publishing Group
Subjectnon prescription drug
beta adrenergic receptor blocking agent
dipeptidyl carboxypeptidase inhibitor
hydroxymethylglutaryl coenzyme A reductase inhibitor
acute coronary syndrome
adult
Article
cardiac patient
cardiology service
cardiovascular mortality
clinical effectiveness
controlled study
emergency ward
female
follow up
health care delivery
hospital discharge
hospital readmission
human
intention to treat analysis
major clinical study
male
outcome assessment
patient compliance
pharmacist
prospective study
Qatar
randomized controlled trial
acute coronary syndrome
aged
cause of death
follow up
methodology
middle aged
mortality
risk factor
statistics and numerical data
very elderly
Acute Coronary Syndrome
Adrenergic beta-Antagonists
Adult
Aged
Aged, 80 and over
Angiotensin-Converting Enzyme Inhibitors
Cause of Death
Female
Follow-Up Studies
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Male
Middle Aged
Patient Discharge
Patient Readmission
Pharmacists
Prospective Studies
Qatar
Research Design
Risk Factors
TitleImpact of a pharmacist-delivered discharge and follow-up intervention for patients with acute coronary syndromes in Qatar: A study protocol for a randomised controlled trial
TypeArticle
Issue Number11
Volume Number6
dc.accessType Abstract Only


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record